durvalumab,tremelimumab
astrazeneca
[]
neoadjuvant tremelimumab/durvalumab elicits responses in gastric/gej adenocarcinoma #gi23 #stomachcancer #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.